Comparative effectiveness of generic nifedipine versus Adalat long-acting nifedipine for hypertension treatment: A multi-institutional cohort study.
blood pressure
generic drug
nifedipine
outcome
Journal
Journal of clinical hypertension (Greenwich, Conn.)
ISSN: 1751-7176
Titre abrégé: J Clin Hypertens (Greenwich)
Pays: United States
ID NLM: 100888554
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
14
03
2022
received:
06
02
2022
accepted:
19
03
2022
pubmed:
7
4
2022
medline:
18
5
2022
entrez:
6
4
2022
Statut:
ppublish
Résumé
This retrospective multi-institutional database analysis aimed to evaluate the blood-pressure-lowering efficacy and clinical outcomes of a generic versus brand-name nifedipine for hypertension management. A total of 12 693 patients who were prescribed a generic or brand-name nifedipine between January 1, 2011, and December 31, 2018, were identified from the Chang Gung Research Database of Chang Gung Memorial Hospitals, Taiwan. Among them, 2112 (21.4%) were prescribed generic nifedipine. After propensity score matching, both the generic and brand-name groups consisted of 2102 patients. At a mean follow-up of 3 years, the changes in office systolic (p for interaction = .791) and diastolic blood pressure (p for interaction = .689) did not differ significantly between the patients who received the generic and the brand-name nifedipine. There was no significant difference between the two study groups regarding the composite of all-cause mortality, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure (hazard ratio 0.98, 95% confidence interval 0.85-1.13; p = .774). In conclusion, the generic nifedipine was comparable to its brand-name counterpart regarding office blood pressure reduction and the composite cardiovascular outcome for the treatment of patients with hypertension.
Identifiants
pubmed: 35384251
doi: 10.1111/jch.14478
pmc: PMC9106077
doi:
Substances chimiques
Drugs, Generic
0
Nifedipine
I9ZF7L6G2L
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-629Informations de copyright
© 2022 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.
Références
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Pharmacoepidemiol Drug Saf. 2019 May;28(5):593-600
pubmed: 30648314
Circ Res. 2019 Mar 29;124(7):1124-1140
pubmed: 30920917
Hypertension. 2013 Dec;62(6):982-7
pubmed: 24041952
JAMA. 2008 Dec 3;300(21):2514-26
pubmed: 19050195
Stat Med. 2019 Feb 28;38(5):751-777
pubmed: 30347461
Circulation. 2018 May 29;137(22):2344-2356
pubmed: 29449338
J Am Soc Hypertens. 2010 Sep-Oct;4(5):244-54
pubmed: 20728422
Blood Press Monit. 2006 Oct;11(5):293-6
pubmed: 16932038
J Clin Hypertens (Greenwich). 2022 May;24(5):621-629
pubmed: 35384251
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
Eur J Pharm Biopharm. 2009 Nov;73(3):311-23
pubmed: 19602438
Am Health Drug Benefits. 2012 Nov;5(7):423
pubmed: 24991338
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Eur Heart J Cardiovasc Pharmacother. 2021 Aug 23;:
pubmed: 34423350
Drugs. 2020 May;80(7):697-710
pubmed: 32279239
Diabetes Res Clin Pract. 2021 Oct;180:109076
pubmed: 34599973
Circulation. 2016 Aug 9;134(6):441-50
pubmed: 27502908
Lancet. 2008 May 3;371(9623):1513-8
pubmed: 18456100
Blood Press. 2010 Feb;19(1):3-10
pubmed: 19929287
J Hypertens. 2010 Aug;28(8):1770-7
pubmed: 20531224
Curr Med Res Opin. 2006 Oct;22(10):1879-92
pubmed: 17022845
J Clin Hypertens (Greenwich). 2020 Dec;22(12):2296-2305
pubmed: 33035392
Eur J Epidemiol. 2016 Apr;31(4):351-68
pubmed: 26620809
Blood Press Suppl. 2005 Jul;1:32-8
pubmed: 16060414
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Hypertension. 2006 Mar;47(3):345-51
pubmed: 16432045
JAMA Cardiol. 2018 Jul 1;3(7):572-581
pubmed: 29800138